Early detection through screening allows for timely intervention with direct-acting antiviral (DAA) therapies, which have high cure rates. Early treatment can prevent the progression to severe liver disease, reduce the risk of liver cancer, and improve overall quality of life. It also has public health benefits by reducing the transmission of HCV within the community.
